Stock info Getinge | Filter  Basic-Info

Getinge

Getinge's head office is located in G�teborg. Getinge mainly operates in the pharmaceutical sector. Getinge is being led by CEO Johan Malmquist. Ulf Grunander is financially responsible for the company as CFO. Between 2006 and 2016 the global pharmaceutical companies gained around 75 percent. Since 2011 the sector is 147 percent higher and over the past year minus 75 percent.

The past year was a good year for Getinge investors

Over the last 12 months (from December 2015 till December 2016), that were loss-making period for the investors in Getinge, the stock lost around 32 percent. The period between August 2011 and August 2016 was a bad period for the investors. The stock lost around 16 percent. Getinge's revenues between 2011 and 2015 were relatively steady and moved between 24,25 billion SEK and 30,24 billion SEK. The net results between 2011 and 2015 were far from constant and fluctuated between 2,67 billion SEK and 1,96 billion SEK.

Over the past 5 years the Swedish company paid out dividends. Over the past 5 years the stock delivered an average dividend return of 17,65 percent.

At the end of 2015 Getinge employed at around 15,75 thousand people.

Getinge' balance mostly financed with equity

At the end of 2015 the pharmaceutical company's balance sheet equaled 53,24 billion SEK. Last year the total debt of the company was 53,24 billion SEK. This equals around 100 percent of the total balance sheet. The Swedish company's price/earnings-ratio was 22. So the market valued the stock at 22 times the 2015' earnings per share. Based on the classical stock valuation theories the Swedish stock can be seen as a value stock.

At the end of 2015 the pharmaceutical company's market capitalization (the number of shares times the market price) equaled around 50,95 billion SEK. At the end of 2015 the Swedish company had around 238,32 million stocks listed.

All the company's financial reports are available here. More information about Getinge can be found it's website. .